Clinical Trials

47 enrolled

Other solid neoplasm

Locally Advanced Solid Tumor

NCT02113878 2024-11-05

Phase Ib Study of BKM120 With Cisplatin and XRT in High Risk Locally Advanced Squamous Cell Cancer of Head and Neck

23 enrolled 22 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Nasopharyngeal Neoplasms

NCT02159066 2024-03-05

LOGIC-2

158 enrolled 40 charts

Dermatologic

Melanoma

NCT01397877 2023-09-06

ENDOPIK

24 enrolled

Gynecologic

Neoplasm Metastasis, Endometrial Neoplasms

NCT02340780 2023-08-22

Buparlisib in Patients With Relapsed and Refractory Chronic Lymphocytic Leukemia

LymphoidOther hematologic neoplasm

14 enrolled 9 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT01591421 2023-08-04

P13Kinase Inhibitor BKM120 in Combination With Panitumumab in Metastatic/Advanced RAS-Wild Type Colorectal Cancer.

Phase 1/2 Completed

22 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT01971489 2023-04-27

Buparlisib, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Advanced Solid Tumors

Phase 1 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT01570296 2023-03-29

BKM120

38 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02756247 2022-10-10

A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma

37 enrolled

Lymphoid

Lymphoma, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT02117817 2022-07-28

Phase I BKM120/Abraxane in Solid Tumors, Expansion Phase Recurrent Endometrial or Ovarian Cancer

Phase 1 Withdrawn

Gynecologic

Ovarian Neoplasms, Endometrial Neoplasms

NCT01540253 2022-07-22

PI3K Inhibitor BKM120 and Docetaxel in Treating Patients With Advanced Solid Tumor That is Locally Advanced, Cannot Be Removed By Surgery, or Metastatic

38 enrolled

Other solid neoplasm

Unspecified Adult Solid Tumor, Protocol Specific

NCT02049541 2022-06-30

Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma

18 enrolled

Lymphoid

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT02220855 2022-04-11

A Study of BKM120 (Buparlisib) in Relapsed or Refractory Thymomas

14 enrolled 14 charts

Thymoma

NCT02000882 2022-02-07

STAR Cape+BKM120 MBC With Brain Met

10 enrolled 11 charts

BreastCNS

Brain Neoplasms, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01806649 2021-10-11

BKM120 in Esophageal Squamous Cell Carcinoma After Failure of First Line Chemotherapy

Phase 2 Terminated

5 enrolled

Gastrointestinal

Esophageal Neoplasms

NCT01816984 2021-10-05

PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

Phase 1/2 Completed

12 enrolled 11 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Salivary Gland Neoplasms, Tongue Neoplasms

NCT01623349 2021-02-10

Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer

118 enrolled

BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms, Recurrence

NCT01695473 2021-01-13

Neoadjuvant BKM120 in High-risk Prostate Cancer

Phase 2 Terminated

11 enrolled 8 charts

Genitourinary

Prostatic Neoplasms

NCT01468688 2020-12-21

A Dose-finding Study of a Combination of Imatinib and BKM120 in the Treatment of 3rd Line GIST Patients

60 enrolled

Sarcoma

3rd Line GIST

NCT01576666 2020-12-19

Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors

BreastCNSGastrointestinal

120 enrolled

Breast Neoplasms, Glioblastoma, Stomach Neoplasms, Colorectal Neoplasms

NCT02154776 2020-12-19

LeeBLet

13 enrolled

Breast Neoplasms

NCT02088684 2020-12-17

Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast Cancer

70 enrolled

Breast Neoplasms

NCT01155453 2020-12-09

A Study to Investigate Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of BKM120 Plus GSK1120212 in Selected Advanced Solid Tumor Patients

113 enrolled

BreastGastrointestinal

Pancreatic Neoplasms, Triple Negative Breast Neoplasms

NCT01285466 2020-12-09

A Trial of Oral BEZ235 and BKM120 in Combination With Paclitaxel With or Without Trastuzumab

110 enrolled

Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT01473901 2020-12-09

A Phase I Dose Escalation Study of BKM120 With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma

38 enrolled

Glioblastoma

NCT01626209 2020-12-09

A Phase I Study of BKM120 in Adult Chinese Patients With Advanced Solid Tumors

BreastGastrointestinalThoracic

32 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms

NCT01634061 2020-12-09

Phase Ib of Abiraterone Acetate Plus BEZ235 or BKM120 in Castration-resistant Prostate Cancer (CRPC) Patients

43 enrolled

Genitourinary

Castration-resistant Prostate Cancer

NCT01934361 2020-12-09

Phase Ib/II Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme

35 enrolled

Glioblastoma

NCT01068483 2020-12-08

Safety of BKM120 Monotherapy in Advanced Solid Tumor Patients

BreastGastrointestinalGynecologic

107 enrolled

Breast Neoplasms, Colonic Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT01283503 2020-12-08

A Study of BKM120 in Adult Japanese Patients With Advanced Solid Tumors

15 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT01629615 2020-10-28

A Trial of BKM120 (a PI3K Inhibitor) in Patients With Triple Negative Metastatic Breast Cancer

50 enrolled 10 charts

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT01363232 2020-10-05

Safety, Pharmacokinetics and Pharmacodynamics of BKM120 Plus MEK162 in Selected Advanced Solid Tumor Patients

BreastGastrointestinalGynecologic

89 enrolled

Ovarian Neoplasms, Pancreatic Neoplasms, Triple Negative Breast Neoplasms

NCT01610284 2020-08-25

BELLE-2

Phase 3 Completed

1,147 enrolled 20 charts

Breast Neoplasms, Neoplasm Metastasis

NCT01349660 2020-06-17

Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma Multiforme

Phase 1/2 Completed

88 enrolled 13 charts

Glioblastoma

NCT02058381 2020-03-09

B-YOND

40 enrolled

Pre-menopausal Breast Cancer

NCT01816594 2019-11-14

NeoPHOEBE

50 enrolled 23 charts

LymphoidOther hematologic neoplasm

Breast Neoplasms

NCT02614508 2019-09-03

Buparlisib and Ofatumumab or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Phase 1 Terminated

1 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02128724 2019-08-01

BKM120

21 enrolled 23 charts

Hypoxia, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01737450 2019-06-24

PIK-ORL

58 enrolled

Head & Neck

Head and Neck Neoplasms, Neoplasm Metastasis, Recurrence, Disease Progression

NCT01289041 2019-05-30

BKM120 as Second-line Therapy for Advanced Endometrial Cancer

70 enrolled 8 charts

Gynecologic

Advanced Endometrial Cancer

NCT01339052 2019-03-19

Phase II Study of BKM120 for Subjects With Recurrent Glioblastoma

65 enrolled 30 charts

Brain Neoplasms, Glioblastoma

NCT01487265 2019-03-06

Trial of Erlotinib and BKM120 in Patients With Advanced Non Small Cell Lung Cancer Previously Sensitive to Erlotinib

37 enrolled 10 charts

Carcinoma, Non-Small-Cell Lung

NCT01741753 2019-02-05

BKM120+Abiraterone Acetate for Metastatic CRPC

Phase 1 Terminated

4 enrolled

Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT01633060 2019-01-30

BELLE-3

Phase 3 Terminated

432 enrolled 20 charts

Breast Neoplasms, Neoplasm Metastasis, Hereditary Sensory and Autonomic Neuropathies

NCT02303041 2019-01-29

Pilot Study of Sonidegib and Buparlisib in Treating Patients With Advanced or Metastatic Basal Cell Carcinoma

Phase 2 Terminated

10 enrolled 11 charts

Dermatologic

Basal Cell Nevus Syndrome, Carcinoma, Basal Cell, Skin Neoplasms

NCT01790932 2019-01-23

BKM120 For Triple Negative Breast Cancer

50 enrolled 8 charts

Breast Neoplasms, Neoplasm Metastasis

NCT01833169 2018-10-19

SIGNATURE